Description

Royalty Pharma’s $425 Million AstraZeneca Bet — Could Cliramitug Become A Blockbuster?

Royalty Pharma reported its second quarter 2026 financial results showcasing continued growth and portfolio diversification across multiple biopharmaceutical royalty interests. The company delivered 6% growth in portfolio receipts and a 14% increase in total receipts, outperforming guidance for the quarter. Return on invested capital was 14.2%, while return on invested equity reached 20.1%, reflecting ongoing efficient capital deployment. Royalty Pharma has deployed $1.1 billion on royalty acquisitions year-to-date, including a notable $425 million agreement for a royalty on AstraZeneca’s cliramitug, a novel therapy targeting transthyretin amyloid cardiomyopathy (ATTR-CM), with blockbuster potential estimated at peak sales between $3 billion and $5 billion. The company continues to manage a broadly balanced portfolio of 19 development-stage pipeline assets, a sixfold increase since 2020. Peak royalty potential from this pipeline now totals approximately $2 billion.